Immunohistochemical staining of the tumor was positive for CK7 (Fig. 4c), CDX2 (Fig. 4e), and CEA expression and negative for CK20 (Fig.SkiptomaincontentAdvertisementSearchallBMCarticlesSearchDownloadPDFCasereportOpenAccessPublished:25January2016Cytokeratin7-positive/cytokeratin20-negativececaladenocarcinomametastatictotheuterinecervix:acasereportMasafumiToyoshima1,4,YutaMomono1,HiromitsuMakino1,TakakoKudo1,NaomiOka2,JunkoSakurada2,HiroyoshiSuzuki2,HideakiKodama3&KosukeYoshinaga1 WorldJournalofSurgicalOncologyvolume 14,Article number: 22(2015)Citethisarticle3435Accesses5Citations1AltmetricMetricsdetailsAbstractBackgroundThevastmajorityofuterinecervicalmalignanciesareprimarycarcinomas,andsecondaryneoplasmsthatmetastasizetotheuterinecervixfromadistantorganareuncommon.Althoughrelativelyrare,metastasestotheuterinecervixfromaprimarycoloncancerhavebeenreported.Wereportararecaseofmetastaticcarcinomaoriginatingfromacecaladenocarcinomawithanunusualcytokeratin7/cytokeratin20immunophenotype.CasepresentationA74-year-oldpostmenopausalJapanesewomanwasreferredtoourhospitalfortheevaluationofauterinetumor.Shehadapastmedicalhistoryofcecalcancerandhadundergonelaparoscopicallyassistedrighthemicolectomyattheageof69 years.Duringfollow-up,shewasfoundtohaveelevatedlevelsofthetumormarkerscarbohydrateantigen19-9(179.7 IU/mL)andcarcinoembryonicantigen(26.9 μg/L).Positronemissiontomography/computedtomographyshowedafocusofhigh18F-fluorodeoxyglucoseuptakeinheruterus.Examinationofacervicalbiopsyfoundapoorlydifferentiatedadenocarcinomathatwasimmunopositiveforcytokeratin(CK)7andcaudal-relatedhomeobox2(CDX2)expressionandimmunonegativeforcytokeratin20expression.Thepatientunderwentradicalhysterectomyandbilateralsalpingo-oophorectomy.Histopathologicalexaminationfoundinvasivegrowthofirregularandatypicalductalhyperplasia.Immunohistochemicalstainingofthetumorspecimenrevealedthesameimmunophenotypeasthebiopsyspecimen.Thececalcancerspecimenfromherprevioussurgerywasalsoexaminedandfoundtohavethesameimmunopheno

NCBISkiptomaincontentSkiptonavigationResourcesHowToAboutNCBIAccesskeysMyNCBISignintoNCBISignOutJournalListHHSAuthorManuscriptsPMC3603700AJRAmJRoentgenol.Authormanuscript;availableinPMC2014Mar1.Publishedinfinaleditedformas:AJRAmJRoentgenol.2013Mar;200(3):484–492.doi: 10.2214/AJR.12.9363PMCID:PMC3603700NIHMSID:NIHMS449402PMID:23436835CancerofUnknownPrimarySites:WhatRadiologistsNeedtoKnowandWhatOncologistsWanttoKnowKyungWonKim,1,2KatherineM.Krajewski,1JyothiP.Jagannathan,1MizukiNishino,1AtulB.Shinagare,1JasonL.Hornick,3andNikhilH.Ramaiya1KyungWonKim1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,022152DepartmentofRadiology,SeoulAsanMedicalCenter,Seoul,KoreaFindarticlesbyKyungWonKimKatherineM.Krajewski1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,02215FindarticlesbyKatherineM.KrajewskiJyothiP.Jagannathan1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,02215FindarticlesbyJyothiP.JagannathanMizukiNishino1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,02215FindarticlesbyMizukiNishinoAtulB.Shinagare1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,02215FindarticlesbyAtulB.ShinagareJasonL.Hornick3DepartmentofPathology,BrighamandWomen’sHospital,HarvardMedicalSchool,Boston,MAFindarticlesbyJasonL.HornickNikhilH.Ramaiya1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,02215FindarticlesbyNikhilH.RamaiyaAuthorinformationCopyrightandLicenseinformationDisclaimer1DepartmentofImaging,Dana-FarberCancerInstitute,HarvardMedicalSchool,450BrooklineAve,Boston,MA,022152DepartmentofRadiology,SeoulAsanMedicalCenter,Seoul,Korea3DepartmentofPathology,BrighamandWomen’sHospital,HarvardMedicalSchool,Boston,MAAddresscorrespondencetoK.W.Kim(moc.liamg@hsamidem)CopyrightnoticeThepublisher'sfinaleditedversionofthisarticleisavaila

The CK7-positive and CK20-negative cohort was the most frequent (Figure 1). We found that 7 tumors did not exhibit profiles in accordance with ...BrowseSubjectAreas?ClickthroughthePLOStaxonomytofindarticlesinyourfield.FormoreinformationaboutPLOSSubjectAreas,clickhere.ArticleAuthorsMetricsCommentsMediaCoverageReaderComments(0)FiguresFiguresAbstractBackgroundDevelopmentoftailoredtreatmentbasedonimmunohistochemicalprofiles(IPs)oftumorsforcancersofunknownprimaryisneeded.Methodology/PrincipalFindingsWedevelopedanalgorithmbasedonprimaryknownadenocarcinomafortestingsensitivityandspecificity.Formalin-fixedparaffin-embeddedtissuesamplesfrom71patientsofunfavorablesubsetsofunknownprimaryadenocarcinomawereobtained.Weexamined15molecularmarkersusingthealgorithmincorporatingtheseIPsandclassifiedthetumoursinto9subsetsbasedontheprimarytumoursite.Thesensitivityandspecificityofthisalgorithmwere80.3%and97.6%,respectively.Apparentprimarysiteswerelungin17patients,digestiveorgansin13,gynecologicalorgansin9,prostatein7,liverorkidneyin6,breastin4,urothelialorganin2,biliarytractandpancreaticprofileinnone,andunclassifiedin13.TheresponseratetochemotherapywashighestforthegynecologicalIPs.PatientswithgynecologicalorlungcancerIPshadlongermedianprogression-freesurvivalthanthosewithothers:11.2monthsforgynecologicalIPs(p<0.001)and6.8monthsforlungIPs(p = 0.05).Lung,digestive,prostate,andgynecologicalprofileswereassociatedwithsignificantlylongermediansurvivaltimethantheotherprofiles.MultivariateanalysisconfirmedthattheIPswereindependentprognosticfactorsforsurvival.Conclusions/SignificanceTheIPsidentifiedinthisstudycanbeusedtofurtherstratifypatientprognosisforunfavorablesubsetsofunknownprimaryadenocarcinoma.Citation:HashimotoK,SasajimaY,AndoM,YonemoriK,HirakawaA,FurutaK,etal.(2012)ImmunohistochemicalProfileforUnknownPrimaryAdenocarcinoma.PLoSONE7(1):e31181.https://doi.org/10.1371/journal.pone.0031181Editor:SyedA.Aziz,HealthCanada,CanadaReceived:August12,2011;Accepted:January3,2012;Published:January27,2

Clipboard,SearchHistory,andseveralotheradvancedfeaturesaretemporarilyunavailable.SkiptomainpagecontentCOVID-19InformationPublichealthinformation(CDC)Researchinformation(NIH)SARS-CoV-2data(NCBI)Preventionandtreatmentinformation(HHS)Español AccesskeysNCBIHomepageMyNCBIHomepageMainContentMainNavigationSearch:SearchAdvancedClipboardUserGuideSaveEmailSendtoClipboardMyBibliographyCollectionsCitationmanagerDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSavecitationtofileFormat:Summary(text)PubMedPMIDAbstract(text)CSVCreatefileCancelEmailcitationSubject:1selecteditem:17549351-PubMedTo:Format:SummarySummary(text)AbstractAbstract(text)MeSHandotherdataSendemailCancelAddtoCollectionsCreateanewcollectionAddtoanexistingcollectionNameyourcollection:Namemustbelessthan100charactersChooseacollection:UnabletoloadyourcollectionduetoanerrorPleasetryagainAddCancelAddtoMyBibliographyMyBibliographyUnabletoloadyourdelegatesduetoanerrorPleasetryagainAddCancelYoursavedsearchNameofsavedsearch:Searchterms:TestsearchtermsWouldyoulikeemailupdatesofnewsearchresults?SavedSearchAlertRadioButtonsYesNoEmail:(change)Frequency:MonthlyWeeklyDailyWhichday?ThefirstSundayThefirstMondayThefirstTuesdayThefirstWednesdayThefirstThursdayThefirstFridayThefirstSaturdayThefirstdayThefirstweekdayWhichday?SundayMondayTuesdayWednesdayThursdayFridaySaturdayReportformat:SummarySummary(text)AbstractAbstract(text)PubMedSendatmost:1item5items10items20items50items100items200itemsSendevenwhentherearen'tanynewresultsOptionaltextinemail:SaveCancelCreateafileforexternalcitationmanagementsoftwareCreatefileCancelYourRSSFeedNameofRSSFeed:Numberofitemsdisplayed:510152050100CreateRSSCancelRSSLinkCopyFulltextlinksSpandidosPublicationsFulltextlinksActionsCiteFavoritesDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSharePermalinkCopyPagenavigationTitle&authorsAbstractSimilararticlesCitedbyPublicationtypesMeSHtermsSubstancesRelatedinformationLinkOut-moreresourcesTitle&authorsAbstractSimilararticlesCitedbyPublicationtypesMeSHter

CancerTopicsCancerHomeBladderCancerBrainCancerBreastCancerCervicalCancerColorectalCancerLeukemia&LymphomaLungCancerMelanomaMultipleMyelomaOvarianCancerPancreaticCancerProstateCancerOverview&FactsRisks&PreventionSymptoms&SignsCancerTypesDiagnosis&TestsYourCancerCareTeamCancerTreatmentCutting-EdgeTreatmentsLiving&ManagingRemission&RecurrenceSupport&ResourcesAllGuideTopicsMoreCancerResourcesNewsReferenceSlideshowsQuizzesVideosQuestions&AnswersFindanOncologistCancerA-ZMoreCancerTopicsCancerReferenceInthisArticleInthisArticleInthisArticleWhatIsAdenocarcinoma?LocationsAdenocarcinomaStartsHowIsAdenocarcinomaDiagnosed?HowIsItTreated?WhatIsAdenocarcinoma?Ifyourdoctortellsyouthatyouhaveadenocarcinoma,itmeansyouhaveatypeofcancerthatstartsintheglandsthatlinetheinsideofoneofyourorgans.Adenocarcinomacanhappeninmanyplaces,likeyourcolon,breasts,esophagus,lungs,pancreas,orprostate.It'snaturaltofeelworriedwhenyoufindoutyouhavecancer,butrememberthattreatmentscansloworstopthedisease.Youmightneedchemotherapy,radiation,targetedtherapy,orsurgery.Youandyourdoctorwilldecideonthebestapproach,basedonwhereyourtumorsaregrowingandhowlongyou'vehadthem.LocationsAdenocarcinomaStartsYourglandsmakefluidsthatyourbodyneedstostaymoistandworkwell.Yougetadenocarcinomawhencellsintheglandsthatlineyourorgansgrowoutofcontrol.Theymayspreadtootherplacesandharmhealthytissue.Adenocarcinomacanstartinyour:Colonandrectum.Thecolon,whichisalsocalledyour"largeintestine,"ispartofyourdigestivesystem.It'salongtubethathelpsremovewaterandnutrientsfromthefoodyoueat.Adenocarcinomaisthemostcommontypeofcoloncancer.Itstartsoutasasmallpolyp,orgrowth,that'susuallyharmlessatfirstbutcanturnintocancer.Thediseasecanalsostartinyourrectum,thepartofyourlargeintestinewheretheleftoverwastefromdigestedfood,calledstool,getspushedoutofyourbody.Breasts.Mostbreastcancersareadenocarcinomas.Theystartintheglandsofthebreastwheremilkismade.Esophagus.Thisisthetubethatcarriesfoodfromyourmouthtoyourstomach.Adenocarcinomausuallystartsinmucusglandsthatli

NCBISkiptomaincontentSkiptonavigationResourcesHowToAboutNCBIAccesskeysMyNCBISignintoNCBISignOutJournalListJPatholTranslMedv.52(5);2018SepPMC6166010JPatholTranslMed.2018Sep;52(5):283–289.Publishedonline2018Aug31.doi: 10.4132/jptm.2018.08.14PMCID:PMC6166010PMID:30235512p40ImmunohistochemistryIsanExcellentMarkerinPrimaryLungSquamousCellCarcinomaKhairunisaAhmadAffandi,NurMayaSabrinaTizen,MuaatamarulainMustangin,andReenaRahayuMdReenaRahayuMdZinKhairunisaAhmadAffandiDepartmentofPathology,UniversitiKebangsaanMalaysiaMedicalCentre,UniversitiKebangsaanMalaysia,KualaLumpur,MalaysiaFindarticlesbyKhairunisaAhmadAffandiNurMayaSabrinaTizenDepartmentofPathology,UniversitiKebangsaanMalaysiaMedicalCentre,UniversitiKebangsaanMalaysia,KualaLumpur,MalaysiaFindarticlesbyNurMayaSabrinaTizenMuaatamarulainMustanginDepartmentofPathology,UniversitiKebangsaanMalaysiaMedicalCentre,UniversitiKebangsaanMalaysia,KualaLumpur,MalaysiaFindarticlesbyMuaatamarulainMustanginReenaRahayuMdReenaRahayuMdZinDepartmentofPathology,UniversitiKebangsaanMalaysiaMedicalCentre,UniversitiKebangsaanMalaysia,KualaLumpur,MalaysiaFindarticlesbyReenaRahayuMdReenaRahayuMdZinAuthorinformationArticlenotesCopyrightandLicenseinformationDisclaimerDepartmentofPathology,UniversitiKebangsaanMalaysiaMedicalCentre,UniversitiKebangsaanMalaysia,KualaLumpur,MalaysiaCorrespondingAuthorReenaRahayuMdZin,MBChB,PhDDepartmentofPathology,FacultyofMedicine,UKMMedicalCenter,JalanYaacobLatif,BandarTunRazak,Cheras56000,KualaLumpur,MalaysiaTel:+603-91455359Fax:+603-91737340E-mail:ym.ude.mku.mkupp@uyaharaneerReceived2018Apr23;Revised2018Aug9;Accepted2018Aug14.Copyright©2018TheKoreanSocietyofPathologists/TheKoreanSocietyforCytopathologyThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.org/licenses/by-nc/4.0)whichpermitsunrestrictednon-commercialuse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.ThisarticlehasbeencitedbyotherarticlesinPMC.Back